- Trial phase
- Commercially Available (LDT)
- Time to market
- Already commercially available in the U.S. as a laboratory developed test (LDT) through the company's CLIA-certified lab. CMS reimbursement has been in effect since January 2024.
- Why 4/10
- CyPath Lung is already commercially available and generating revenue with no pending FDA PDUFA, pivotal readout, or other hard binary catalyst in the next 12 months. The defining regulatory binary (CMS reimbursement determination) passed in early 2024. ImpactScore is capped at 4 per the rubric for an approved/marketed product with no imminent regulatory decision.
CyPath Lung is already commercial and generating revenue, so the next catalysts are commercial execution metrics (quarterly sales growth, test volumes, physician adoption) and data readouts from the large-scale longitudinal clinical study initiated in March 2026. The stock has fallen ~90% from its 52-week high and recently dipped after Q3 earnings, making sustained sales acceleration the key swing factor for the shares.
Price Chart
Executive Summary
CyPath Lung is a noninvasive, sputum-based diagnostic test for early-stage lung cancer, developed and commercialized by bioAffinity Technologies (Nasdaq: BIAF). The test uses flow cytometry and an AI algorithm to detect cancer cells in a patient's sputum sample and is offered as a laboratory developed test (LDT) through the company's CLIA-certified lab. It has been commercially available since at least 2023 with CMS Medicare reimbursement in place since January 2024. The company reported Q3 2026 revenue of $1.07 million from the test, with sales more than doubling year-over-year through the first three quarters of 2026. The stock trades near $1.90, down roughly 90% from its 52-week high, and the company recently completed a $4 million direct offering to fund working capital and sales growth.
How It Works
CyPath Lung is a noninvasive diagnostic test that analyzes a patient's sputum (phlegm) sample using flow cytometry and an artificial intelligence algorithm. The test looks for abnormal cells that may indicate lung cancer. Because it only requires a sputum sample rather than a tissue biopsy or blood draw, it is less invasive than many alternatives. The test is run in the company's own CLIA-certified laboratory as a laboratory developed test (LDT).
Trial Status
CyPath Lung is commercially available and generating revenue. A large-scale longitudinal clinical study was initiated in March 2026 to further validate the test. The company is also advancing the test for lung cancer survivor surveillance and exploring applications in asthma and COPD diagnosis.
The Two-Sided Case
Upcoming Catalysts
- Q4 2026 / full-year 2026 earnings report (expected early 2027) with CyPath Lung sales and test volume updates
- Data readouts from the large-scale longitudinal clinical study (initiated March 2026)
- Potential expansion into lung cancer survivor surveillance indication
- Further distribution expansion through the AvMEDICAL federal healthcare partnership
Source Filing
The SecBot filing or press-release report that triggered this drug report:
bioAffinity Technologies, Inc. 8-K BIAF ·Originating report